Focà Emanuele, Motta Davide, Pollara Caterina, Brianese Nigritella, Gotti Daria, Albini Laura, Quiros-Roldan Eugenia, Torti Carlo, Manca Nino
Infectious Diseases Department, University of Brescia, Brescia, Italy.
New Microbiol. 2012 Apr;35(2):227-31. Epub 2012 Mar 31.
Our objective was to explore whether positive human cytomegalovirus (HCMV) DNAemia at baseline impaired CD4+ T-cell increase after 1 year of HAART. A sub-study of a randomized clinical trial in selected patients with <200 cell/mm CD4+ at baseline was conducted. Six out of 30 patients had detectable HCMV DNAemia at baseline, all reaching HCMV suppression at week 52 after HAART (only 1 of them was treated with valgancyclovir). No significant differences were found between patients with detectable or undetectable HCMV DNAemia in terms of CD4+ T-cell increase and HIV RNA response to HAART. Although some data may favor HCVM pre-emptive therapy to decrease immune activation, our results do not indicate that this practice may increase CD4+ T-cell count after HAART. At the same time, HAART proved effective in reducing HCMV DNAemia without the need for a specific therapy.
我们的目的是探讨基线时人巨细胞病毒（HCMV）DNA血症阳性是否会损害高效抗逆转录病毒治疗（HAART）1年后CD4+T细胞的增加。对基线时CD4+细胞<200个/mm的选定患者进行的一项随机临床试验的子研究。30名患者中有6名在基线时可检测到HCMV DNA血症，所有患者在HAART后第52周时HCMV均得到抑制（其中只有1名患者接受了缬更昔洛韦治疗）。在可检测到或未检测到HCMV DNA血症的患者之间，在CD4+T细胞增加和HIV RNA对HAART的反应方面未发现显著差异。尽管一些数据可能支持HCMV抢先治疗以减少免疫激活，但我们的结果并不表明这种做法可能会增加HAART后CD4+T细胞计数。同时，HAART被证明在无需特定治疗的情况下可有效降低HCMV DNA血症。
